Chief Medical Officer at Bioage Labs and Pharma and biotech Consultant at Rubin Pharma.
Dr. Rubin received a BA from Occidental College and his M.D. from Rush Medical College. He is board certified in internal medicine completing his post-graduate training at the University of Wisconsin Hospital and Clinics.
Dr. Rubin currently working a Chief Medical Officer at Bioage Labs and as pharma and biotech Consultant at Rubin Pharma.
Prior to joining miRagen,Dr. Rubin was Senior Vice President of Research and Development and Chief Medical Officer at XOMA. Ltd from 2011 – 2015. He was Chief Executive Officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and President and Chief Executive Officer of Critical Therapeutics, Inc. from 2002 to 2007.
From 1996 to 2002, Dr. Rubin was associated with Sepracor, where he served as Senior Vice President, Development, and later as Executive Vice President, Research & Development.
From 1993 to 1996, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, most recently as Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. He was associated with Abbott from 1987 to 1993, including as Vice President, Immunology and Endocrinology, where he successfully advanced zileuton, the first and only approved 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma.
Visit website: https://www.miragen.com/person/paul-rubin/
See also: BIOAGE - Developing a broad pipeline of therapies to extend human healthspan and lifespan
Paul Rubin News
BioAge's anti-ageing drug to treat Covid-19 enters phase 2 trial
Longevity Technology - 22-Mar-2021
Reverses immune ageing and can prevent death from coronavirus infection in the elderlyRead more...
Bioage's lead therapies moved closer to the clinic
Longevity Technology - 03-Dec-2020
Lead therapies of BioAge to treat age related diseases enter phase 2 trialsRead more...